One of three BCAAs. Glucogenic (catabolised to succinyl-CoA). Catabolised extrahepatically by BCKDH — same enzyme complex as Leu/Ile. Deficiency in MSUD (maple syrup urine disease).
Half-Life & Elimination Curve (PO: 1h)
Plasma (PO)t½ Decay (1h)
0×t½0h100%(82.6 mg/L)
1×t½1h50%(41.3 mg/L)
2×t½2h25%(20.7 mg/L)
3×t½3h12.5%(10.3 mg/L)
4×t½4h6.3%(5.16 mg/L)
5×t½5h3.1%(2.58 mg/L)
Elimination t½1h (PO)
Rate Constant (ke)0.693 h⁻¹
Time to Peak (Tmax)49m
Est. Peak (Cmax)82.6 mg/L
Clearance (CL)12.1 L/h
97% Washout (5×t½)5h
Dosing Guidelines
Oral (PO): Typical 2.67 g (Range: 2–4 g)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 95% · Volume of Distribution (Vd): 17.5 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 15930473]